The new year brings new perspectives and ideas. At Illumina, we are evolving our culture of communication and our intention is to share more details about our innovation roadmap of exciting technologies to enable groundbreaking science with Illumina solutions.
We are reinventing our monthly newsletter to become an informative communication channel on “all things” multiomics. Subscribe today and stay tuned, there is so much to come in 2025… and beyond.
Now available - Illumina Single Cell Prep is compatible across Illumina high-throughput NGS platforms, including
Illumina Protein Prep (IPP) can be used to perform NGS-based proteomics analysis using either human plasma or serum as input sample types.
View our video, 'Uncovering the next application of multiomics in biology' for an overview of IPP and other multiomics applications.
Illumina Protein Prep (IPP) is a comprehensive high-throughput proteomics solution that integrates trusted Illumina sequencing by synthesis (SBS) chemistry with the high sensitivity of the Standard BioTools SomaScan® proteomics assay.
Illumina Single Cell 3' RNA Prep (formerly Fluent PIPSeq™ V) makes scRNA-Seq accessible for more labs with an easy, scalable, and microfluidics-free workflow. Researchers can undertake larger and more varied multiomics studies without the budget or technology constraints of other single-cell approaches.
Published by Novo Nordisk, this large study to profile the proteome of obese patients treated with semaglutide aimed to uncover insights into the mode of action of the drug. This publication showcases the potential of using proteomic signatures to identify possible novel indications for semaglutide. While this study used microarray-based proteomic analyses with SomaScan® assay v4.1, the next-generation sequencing (NGS)-based Illumina Protein Prep shows a very good correlation with SomaScan and delivers market-leading precision for high-throughput, aptamer-based proteome profiling.
Research and medical genomics require comprehensive, scalable methods for the discovery of novel disease targets, evolutionary drivers and genetic markers with clinical significance. In this Nature Biotechnology publication, authors demonstrate the performance of DRAGEN across 3,202 whole-genome sequencing datasets by generating fully genotyped multisample variant call format files and demonstrate its scalability, accuracy and innovation to further advance the integration of comprehensive genomics.
Research teams from Valencia, Spain and their collaborators for this study combined single-cell RNA sequencing and spatial transcriptomics to investigate the endometrial decidualization resistance (DR) defects in patients with history of severe preeclampsia (sPE) to reveal significant endometrial changes at macro, micro and cellular levels. The study highlights the value of using a comprehensive multiomic approach to uncover critical molecular underpinnings associated with decidualization defects in the context of sPE.